Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mediskin is an innovative medical-grade topical skincare formulation developed by RSL Revolutionary Labs in collaboration with Promed Bioscience. It is specifically designed to treat dermatological side effects and wounds in oncology patients undergoing cancer treatment, such as radiation-induced dermatitis and other skin toxicities. The primary active ingredient is **CollX3**, a novel water-soluble triple-helix atelocollagen complex. Mediskin works by providing a biocompatible structural scaffold that promotes wound healing and skin tissue regeneration. The project is supported by the European Union's NextGenerationEU plan and is currently being evaluated in multicenter clinical trials (e.g., NCT05588973) to assess its efficacy in wound healing and skin repair for cancer patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mediskin.